Evidence map›Paper›PMID 26406322›Full record

ArticlePloS one2015

Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.

Chiara Ruggeri, Nyssa Drinkwater, Komagal Kannan Sivaraman, Rebecca S Bamert, Sheena McGowan, Alessandro Paiardini

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Docking Screens for Novel Ligands Conferring New Biology.Journal of medicinal chemistry · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chiara RuggeriDipartimento di Scienze biochimiche "A. Rossi Fanelli", Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185, Roma, Italy.
Nyssa DrinkwaterDepartment of Microbiology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia.
Komagal Kannan SivaramanDepartment of Microbiology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia.
Rebecca S BamertDepartment of Microbiology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia.
Sheena McGowanDepartment of Microbiology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton Campus, Melbourne, Victoria, 3800, Australia.
Alessandro PaiardiniDipartimento di Biologia e Biotecnologie "Charles Darwin", Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185, Roma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for the discovery of antimalarial agents. In order to identify dual inhibitors of both proteins, we developed a hierarchical virtual screening approach, followed by in vitro evaluation of the highest scoring hits. Starting from the ZINC database of purchasable compounds, sequential 3D-pharmacophore and molecular docking steps were applied to filter the virtual 'hits'. At the end of virtual screening, 12 compounds were chosen and tested against the in vitro aminopeptidase activity of both PfA-M1 and PfA-M17. Two molecules showed significant inhibitory activity (low micromolar/nanomolar range) against both proteins. Finally, the crystal structure of the most potent compound in complex with both PfA-M1 and PfA-M17 was solved, revealing the binding mode and validating our computational approach.

Indexed as

AminopeptidasesAntimalarialsBinding SitesComputational BiologyCrystallography, X-RayDrug DiscoveryModels, MolecularMolecular Docking SimulationPlasmodium falciparumProtease InhibitorsProtozoan ProteinsStructure-Activity RelationshipAminopeptidasesAntimalarialsProtease InhibitorsProtozoan Proteins

Identifiers

PMID26406322
PMCPMC4583420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.